Abvc biopharma announces new pct filings for mdd and adhd treatments

Fremont, ca, sept. 01, 2021 (globe newswire) -- via newmediawire – abvc biopharma, inc. (nasdaq: abvc), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, cns, and ophthalmology, today announced it has filed new pct (patent cooperation treaty) applications in connection with its medicines that treat major depressive disorder (mdd) and attention-deficit hyperactivity disorder (adhd). the two pct applications describe the treatment methods of oral administrating compositions containing radix polygalae (polygala tenuifolia willd) extract (pdc-1421). pdc-1421 is the active ingredient for both the company's mdd and adhd drugs.
ABVC Ratings Summary
ABVC Quant Ranking